Global Anal Fissure Treatment Market Is Estimated to Grow at 7.6% CAGR By 2023 | Market Research Future
Global
Anal Fissure Treatment Market Research Report: Information, by Treatment Type
(Medication and Surgery), Route of Administration (Oral and Topical), End User
(Hospitals & Clinics and Research & Academic institutes) and Region
(North America, Europe, Asia-Pacific and Middle East & Africa) - Forecast
till 2027
Anal Fissure Treatment Market Highlights
The Global Anal Fissure
Treatment Market is expected to rise and touch a
valuation of USD 2,526.5 million by 2023, at a 7.6% CAGR during the forecast
period (2018-2023). Anal fissures are small tears near the mucosal lining of
the anus. Deeper cuts may take a combination of oral and topical medicine to
alleviate the pain.
The anal fissure treatment
market is expected to thrive owing to the booming pediatric and geriatric
patient pool. Advances in technology coupled with various treatment options is
likely to lead to a windfall for the market over the forecast period. High
incidence of constipation is predicted to drive the need for anal fissure
treatments. This is backed by vulnerability of the elderly which find it
difficult to pass stools properly. According to the American
Gastroenterological, nearly 33% of Americans above 60 experience the condition.
Unhealthy lifestyles adopted by
patients is likely to cause the condition and boost the market demand.
Popularity of over-the-counter (OTC) drugs may spur the market growth owing to
need for rapid treatment options. Drug manufacturers have shifted their focus
to developing economies which offer lucrative growth avenues.
Segmentation:
The anal fissure treatment
market is segmented by treatment type, route of administration, and end-user.
By treatment type, oral held
78.3% share of the anal fissure treatment market in 2017, followed by topical
(16%) and others (5.7%). Oral segment had a valuation of USD 1,284.1 million in
2017 and inflate to USD 2,004.2 million by 2023. Oral medicines include calcium
channel blockers and pain-relieving agents such as Tribenzo and LOMOTIL drugs.
On the other hand, topical medications can generate close to USD 405.8 million
by 2023 at a CAGR of 7.7% during the assessment period.
By route of administration,
medications held close to 86.1% share of the market in 2017, followed by
surgery (13.9%). Surgery has a high success rate compared to other forms of
medical therapy but are considered expensive. This segment can exhibit 6.9%
CAGR over the assessment period to attain a value of USD 339.5 million by 2023.
On the other hand, medications can generate close to USD 2,186.9 million by
2023 at a CAGR of 7.7% during the forecast period. This can be attributed to
various topical or oral medications proposed to patients as alternatives to
surgery.
By end-user, hospitals &
clinics held the largest market share in 2017 owing to the growing patient
visits for anal fissure treatments. Improved healthcare facilities in
developing countries are likely to balloon the segment valuation to USD 1,717.1
million by 2023.
Research & academic
institutes can exhibit a 7.7% CAGR during the forecast period to generate close
to USD 617.6 million by 2023.
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/3841
Regional
Analysis:
Region-wise, the anal fissure
treatment market includes Americas, Europe, Asia Pacific (APAC), and
Rest-of-the-World (RoW).
Americas accounted for 39.1%
market share in 2017, followed by Europe (26.7%) and APAC (20%). The Americas
are predicted to touch a valuation of USD 1,000.6 million by 2023 at a CAGR of
7.8% over the forecast period. This can be credited to rising number of cases of
inflammatory bowel disease among the American populace.
The Europe anal fissure
treatment market is likely to attain close to USD 678.1 million by 2023. This
can be credited to sedentary lifestyles and improper eating habits of residents
in the region. In addition, cases of chronic constipation and food allergies
among children can elicit market demand.
The APAC region is projected to
register 7.9% CAGR during the forecast period. This can be attributed to new
product launches by pharmaceutical and biotechnology companies. The region can
touch a size of USD 513.9 million by 2023.
Competitive
Analysis:
Major names operational in the
anal fissure treatment market are AstraZeneca (U.K.), Abbott Laboratories
(U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Eisai Co. Ltd. (Japan),
Cigna (U.S.), Bayer AG (Germany), Taro Pharmaceutical Industries Ltd. (Israel),
Allergan Inc. (U.S.), Valeant Pharmaceuticals International Inc (Canada), Teva
Pharmaceutical Industries Ltd. (Israel), and Cook (U.S.).
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/anal-fissure-treatment-market-3841
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment